Abstract: Introduction: the review is devoted to clinical results of the use of radiological and endovascular interventionsin intrahepatic cholangiocarcinoma: chemoinfusion, chemo- and radioembolization of the hepatic artery, preoperative embolization of right branch of portal vein. Aim: was to evaluate and compare the effectiveness of methods of intravascular therapy for intrahepatic cholangiocarcinoma. Materials and methods: article presents an analysis of 50 scientific literature sources in leading domestic and foreign scientific journals. Results: it was found that intra-arterial treatment methods have approximately the same clinical efficacy. Chemoinfusion is a technically simple and effective method of treatment, prospects of which are associated with the creation of new chemotherapy drugs and therapeutic regimens. Chemoembolization is most effective for hypervascular cholangiocarcinoma. The question of its use in a neoadjuvant mode requires study, even in resectable cases, it helps to reduce the biological activity of the tumor. Radioembolization (RE) effectively slows down the growth of cholangiocarcinoma and is well tolerated by patients, but long-term results are little bit worse to those of infusion and embolization. The procedure seems to be technically difficult and requires expensive logistics. When solving these problems, ER can become one of the most important methods of treating cholangiocarcinoma, especially when the tumor is resistant to other methods of therapy. Preoperative portal vein embolization is routinely used in clinical practice. However, operations performed after this procedure account for only 3-6% of all liver resections. The wider application of this technically simple and safe technique seems logical. Conclusions: in the treatment of cholangiocarcinoma, a combined approach should be used with the use of surgical, X-ray endovascular and other methods of anticancer therapy: this makes it possible to expand possibilities of treating patients and achieve improved long-term results. References 1. Datta J, Narayan RR, Kemeny NE, D’Angelica MI. Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases (review). JAMA Surg. 2019; 154(8): 768-776. https://doi.org/10.1001/jamasurg.2019.1694 2. Rutkin IO, Granov DA, Polysalov VN, et al. Combination of cytoreductive surgery and implantation of intra-arterial infusion systems in the treatment of unresectable liver tumors. Voprosy Onkologii. 2007; 53(2): 206-209 [In Russ]. 3. Generalov MI, Balakhnin PV, Tsurkan VA, et al. Diagnosis and treatment of toxic complications of regional chemotherapy through percutaneously implanted systems. Diagnosticheskaja i Intervencionnaya Radiologiya. 2007; 1(3): 46-51 [In Russ]. 4. Imamine R, Shibata T, Shinozuka K, Togashi K. Complications in hepatic arterial infusion chemotherapy: retrospective comparison of catheter tip placement in the right/left hepatic artery vs. the gastroduodenal artery. Surg. Today. 2017; 47(7): 851-858. 5. Kozlov AV, Tarazov PG, Polikarpov AA, Polysalov VN. Possibility of regional chemotherapy in patients with cancer of the liver and biliary ducts complicated by obstructive jaundice. Rossijskij Onkologicheskij Zhurnal. 2004; 1: 11-15 [In Russ]. 6. Konstantinidis IT, Do RKG, Gultekin GH, et al. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potentional role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann. Surg. Oncol. 2014; 21(8): 2675-2683. https://doi.org/10.1245/s10434-014-3649-y 7. Konstantinidis IT, Koerkamp BG, Do RKG, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016; 122(5): 758-765. https://doi.org/10.1002/cncr.29824 8. Sinn M, Nicolaou A, Gebauer B, et al. Hepatic arterial infusion with oxaliplatin and 5-FU/folinic acid for advanced biliary tract cancer: a phase II study. Dig. Dis. Sci. 2013; 58(8): 2399-2405. https://doi.org/10.1007/s10620-013-2624-y 9. Wang X, Hu J, Caj G, et al. Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma. Radiology. 2017; 283(2): 580-589. https://doi.org/10.1148/radiol.2016160572 10. Thiels CA, D’Angelica MI. Hepatic artery infusion pumps (review). J. Surg. Oncol. 2020; 122(1): 70-77. https://doi.org/10.1002/jso.25913 11. Savic LJ, Chapiro J, Geschwind J-FH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects (review). Hepatobiliary Surg. Nutr. 2017; 6(1): 7-21. https://doi.org/10.21037/hbsn.2016.11.02 12. Lewis AL, Hall B. Toward a better understanding of the mechanism of action for intra-arterial delivery of irinotecan from DC Bead (DEBIRI). Future Oncology. 2019; 15(17): 2053-2068. https://doi.org/10.2217/fon-2019-0071 13. Faramazzalian A, Armitage KB, Kapoor B, Kalva SP. Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures. Semin. Intervent. Radiol. 2015; 32(2): 209-216. https://doi.org/10.1055/s-0035-1549379 14. Matsui Y, Figi A, Horikawa M, et al. Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. Diagn. Interv. Imag. 2017; 98(12): 827-835. https://doi.org/10.3748/wjg.v25.i31.4360 15. Newgard BJ, Getrajdman GI, Erinjeri JP, et al. Incidence and consequence of nontarget embolization following bland hepatic arterial embolization. Cardiovasc. Intervent. Radiol. 2019; 42(8): 1135-1141. https://doi.org/10.1007/s00270-019-02229-2 16. Dolgushin BI, Virshke ER, Kosyrev VJ, et al. Transarterial chemoembolization in the treatment of inoperable patients with nodular cholangiocarcinoma. Annaly Khirurgicheskoy Gepatologii. 2015; 20(3): 24-30 [In Russ]. https://doi.org/10.16931/1995-5464.2015324-30 17. Park S-Y, Kim JH, Yoon H-J, et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin. Radiol. 2011; 66(4): 322-328. https://doi.org/10.1016/j.crad.2010.11.002 18. Gusani NJ, Balaa FK, Steel JL, et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J. Gastrointest. Surg. 2008; 12(1): 129-137. https://doi.org/10.1007/s11605-007-0312-y 19. Burger I, Hong K, Schulik R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J. Vasc. Interv. Radiol. 2005; 16(3): 353-361. https://doi.org/10.1097/01.RVI.0000143768.60751.7 20. Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011; 117(7): 1498-1505. https://doi.org/10.1002/cncr.25625 21. Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int. J. Cancer. 2012; 31(3): 733-740. https://doi.org/10.1002/ijc.26407 22. Popov VV, Polikarpov AA, Alentiev SA, et al. Possibilities of regional chemotherapy in the treatment of unresectable cholangiocarcinoma. Klinicheskaja Patofisiologija. 2016; 3-1(22): 21-24 [In Russ]. https://doi.org/10.1111/liv.12364 23. Li J, Wang Q, Lei Z, et al. Adjuvant transarterial chemoembolization following liver resection for intrahepatic cholangiocarcinoma based on survival risk stratification. Oncologist. 2015; 26(6): 640-647. https://doi.org/10.1634/theoncologist.2014-0470 24. Lu Z, Liu S, Yi Y, et al. Serum gamma-glutamyl transferase levels affect the prognosis in patients with intrahepatic cholangiocarcinoma who receive postoperative adjuvant transcatheter arterial chemoembolization: a propensity score matching study. Int. J. Surg. 2017; 37: 24-28. https://doi.org/10.1016/j.ijsu.2016.10.015 25. Wu ZF, Zhang HB, Yang N, et al. Postoperative adjuvant transcatheter arterial chemoembolization improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series. Eur. J. Surg. Oncol. 2012; 38(7): 602-610. https://doi.org/10.1016/j.ejso.2012.02.185 26. Park HM, Yun SP, Lee EC, et al. Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann. Surg. Oncol. 2016; 23(13): 4392-4400. https://doi.org/10.1245/s10434-016-5454-2 27. Ge Y, Jeong S, Luo G-J, et al. Transarterial chemoembolization versus percutaneous microwave coagulation therapy for recurrent unresectable intrahepatic cholangiocarcinoma: development of a prognostic nomogram. Hepatobiliary Pancreat. Dis. Int. 2020; 19(2): 138-146. https://doi.org/10.1016/j.hbpd.2020.02.005 28. Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc. Intervent. Radiol. 2008; 31(5): 883-888. https://doi.org/10.1007/s00270-008-9336-2 29. Aliberti C, Carandina R, Sarti D, et al. Chemoembolization with drug-eluting microspheres loaded with doxorubicin for the treatment of cholangiocarcinoma. Anticancer Res. 2017; 37(4): 1859-1863. https://doi.org/10.21873/anticanres.11522 30. Kuhlman JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur. J. Gastroenterol. Hepatol. 2012; 24(4): 437-443. https://doi.org/10.1097/MEG.0b013e3283502241 31. Schiffman SC, Metzger T, Dubel G, et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann. Surg. Oncol. 2011; 18(2): 431-438. https://doi.org/10.1245/s10434-010-1333-4 32. Ray CE, Edwards A, Smith MT, et al. Meta-analysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J. Vasc. Interv. Radiol. 2013; 24(8): 1218-1226. https://doi.org/10.1016/j.jvir.2013.03.019 33. Radosa CG, Radosa JC, Grosche-Schlee S, et al. Holmium-166 radioembolization in hepatocellular carcinoma: feasibility and safety of a new treatment option in clinical practice. Cardiovasc. Intervent. Radiol. 2019; 42(3): 405-412. https://doi.org/10.1007/s00270-018-2133-7 34. Gangi A, Shah J, Hatfield N, et al. Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: Results of a single institution retrospective study. J. Vasc. Interv. Radiol. 2018; 29(8): 1101-1108. https://doi.org/10.1016/j.jvir.2018.04.001 35. Reimer P, Virarkar MK, Binnenhei M, et al. Prognostic factors in overall survival of patients with unresectable intrahepatic cholangiocarcinoma treated by means of yttrium-90 radioembolization: results in therapy-na?ve patients. Cardiovasc. Intervent. Radiol. 2018; 41(5): 744-752. https://doi.org/10.1007/s00270-017-1871-2 36. Al-Adra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur. J. Surg. Oncol. 2015; 41(1): 120-127. https://doi.org/10.1016/j.ejso.2014.09.007 37. Zhen Y, Liu B, Chang Z, et al. A pooled analysis of transarterial radioembolization with ittrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. Onco Targets Ther. 2019; 12: 4489-4498. https://doi.org/10.2147/OTT.S.202875 38. Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann. Surg. Oncol. 2015; 22(9): 3102-3108. https://doi.org/10.1245/s10434-014-4365-3 39. Bargellini I, Mosconi C, Pizzi G, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: Results of a multicenter retrospective study. Cardiovasc. Intervent. Radiol. 2020; 43(9): 1305-1314. https://doi.org/10.1007/s00270-020-02569-4 40. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2019; 6(1): 51-59. https://doi.org/10.1001/jamaoncol.2019.3702 41. White J, Carolan-Rees G, Dale M, et al. Yttrium-90 transarterial radioembolization for chemotherapy-refractory intrahepatic cholangiocarcinoma: a prospective, observational study. J. Vasc. Interv. Radiol. 2019; 30(8): 1185-1192. https://doi.org/10.1016/j.jvir.2019.03.018 42. Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis. J. Vasc. Interv. Radiol. 2020; 31(7): 1035-1043. https://doi.org/10.1016/j.jvir.2020.02.008 43. Akinwande O, Shah V, Mills A, et al. Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution: image-based efficacy and comparative toxicity. Hepatic Oncology. 2017; 4(3): 75-81. https://doi.org/10.2217/hep-2017-0005 44. Currie BM, Soulen MC. Decision making: intra-arterial therapies for cholangiocarcinoma – TACE and TARE. Semin. Intervent. Radiol. 2017; 34(2): 92-100. https://doi.org/10.1055/s-0037-1602591 45. Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann. Surg. Oncol. 2013; 20(12): 3779-3786. https://doi.org/10.1245/s10434-013-3127-y 46. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J. Surg. Oncol. 2015; 111(2): 213-220. https://doi.org/10.1002/jso.23781 47. Yang L, Shan J, Shan L, et al. Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. J. Gastrointest. Oncol. 2015; 6(5): 570-588. https://doi.org/10.3978/j.issn.2078-6891.2015.055 48. Wright GP, Perkins S, Jones H, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a comparison of surgical resection with intra-arterial therapies. Ann. Surg. Oncol. 2018; 25(1): 83-90. https://doi.org/10.1245/s10434-017-6110-1 49. Ebata T, Yokoyama Y, Igami T, et al. Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations. Dig. Surg. 2012; 29(1): 23-29. https://doi.org/10.1159/000335718 50. Higuchi R, Yamamoto M. Indications for portal vein embolization in perihilar cholangiocarcinoma. J. Hep. Bil. Pancr.Sci. 2014; 21(86): 542-549.
Abstract: Aim: was to estimate first own results of arterial radioembolization (RE) in patients with primary or metastatic liver malignancy. Materials and methods: in 2009, RE of the right (n=3) or left (n=1) hepatic artery using Yttrium-90 glass microspheres (Therasphere) was performed in 4 patients: 3 with hepatocellular carcinoma on cirrhosis complicated by portal vein branch thrombosis (contraindication for chemoembolization), and 1 patient with colorectal liver metastases. Results: all RE procedures were technically successful. The radiation dose to the tumor was 1 20-150 Gy The post embolization syndrome was minimal and uncomplicated. After RE, partial tumor response and stabilization were noted in 2 patients each. Patients survived from 14 to 32 months. Conclusion: RE is well-tolerated and safe procedure causing significant local damage of liver tumor. According to our first experience, RE is a very promising method for treatment of hepatic malignancies. References 1. Tarazov P.G. Arterial radioembolization of liver malignancies with ittrium-90 microspheres (review). Voprosy onkologii. 2013; 59(4): 428-434 [In Russ]. 2. Lewandowski R.J., Geschwind J.-F., Liapi E., Salem R. Transcatheter intraarterial therapies: Rationale and overview. Radiology. 2011; 259(3): 641-657. 3. Powerski M.J., Scheurig-Muenkel C., Banzen J., Schnappauff D., Hamm B., Gebauer B. Clinical practice in radioembolization of hepatic malignancies: A survey among interventional centers in 4. Seidensticker R., Seidensticker M., Damm R., Mohnike K., Schutte K., Malfwertheiner P., Van Buskirk M., Pech M., Amthauer H., Ricke J. Hepatic toxicity after radioembolization of the liver using 90Y-micro- spheres: Sequential lobar versus whole liver approach. Cardiovasc. Intervent. Radiol. 2012; 35(5): 1109-1118. 5. Garin E. Radioembolisation of hepatocellular carcinoma patients using 90Y-labelled microspheres: Towards a diffusion of the technique? Eur. J. Nucl. Med. Mol. Imaging. 2011; 38(12): 2114-2116. 6. Atassi B., Bangash A.K., Lewandowski R.J., Ibrahim, Kulik L., Mulcahy M.F., Ryu R.K., Sato K.T., Miller F.H., Omary R.A., Salem R. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J. Vasc. Interv. Radiol. 2008; 19(5): 691-697. 7. Jakobs T.F., Saleem S., Atassi B., Reda E., Lewandowski R.J., Yaghmai V., Miller F., Ryu R.K., Ibrahim 5., Sato K.T., Kulik L.M., Mulcahy M.F., Omary R., Murthy R., Reiser M.F., Salem R. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90Yttrium microspheres. Dig. Dis. Sci. 2008; 53(9): 2556-2563. 8. Naymagon S., Warner R.R.P., Patel K., Harpaz N., Machac J., Weintraub J.L., Kim M.K. Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: An institutional experience and review of the literature. Dig. Dis. Sci. 2010; 55(9): 24502458. 9. Salem R., Lewandowski R.J., Mulcahy M.F., Riaz A., Ryu R.K., Ibrahim S., Atassi B., Baker T., Gates V., Miller F.H., Sato K.T., Wang E., Gupta R., Benson A.B., Newman S.B., Omary R.A., Abecassis M., Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology. 2010; 138(1): 52-64. 10. Salem R., Gilbertsen M., Butt Z., Memon K., Vouche M., Hickey R., Baker T., Abecassis M.M., Atassi R., Riaz A., Cella D., Burns J.L., Ganger D., Benson A.B., Miulcahy M.F., Kulik L., Lewandowsi R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin. Gastroenterol. Hepatol. 2013; 11(10): 1358-1365. 11. Kim YH., Kim D.Y Yttrium-90 radioembolization for hepatocellular carcinoma: What we know and what we need to know. Oncology. 2013; 84 (suppl.1): 34-39. 12. Memon K., Kulik L., Lewandowski R.J., Mulcahy M.F., Benson A.B., Ganger D., Riaz A., Gupta R., Vouche M., Gates V.L., Miller F.H., Omary R.A., Salem R. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. J. Hepatol. 2013; 58(1): 73-80. 13. Moreno-Luna L.E., Yang J.D., Sanchez W., Paz- Fumagalli R., Harnois D.M., Mettler T.A., Gansen D.N., de Groen P.C., Lazaridis K.N., Menon K.W.N., LaRusso M.F., Alberts S.R., Gores G.J., Fleming C.J., Slettedahl S.W.. Harmsen W.S., Therneau T.M., Wiseman G.A., Andrews J.C., Roberts L.R. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 2013; 36(3): 714-723. 14. Tsai A.L., Burke C.T., Kennedy A.S., Moore D.T., Mauro M.A., Dixon R.D., Stavas J.M., Bernard S.A., Khandani A.H., O’Neil B.H. Use of yttrium-90 mocrospheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J. Vasc. Interv. Radiol. 2010; 21(9): 1377-1384. 15. Mazzaferro V., Sposito C., Bhoori S., Romito R., Chiesa C., Morosi C., Maccauro M., Marchiano A., Bongini M., Lanocita R., Civelli E., Bombardien E., Camerini T., Spreafico C. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology. 2013; 57(5): 1826-1837. 16. Stubbs R.S., Wickremesekera S.K. Selective internal radiation therapy (SIRT): A new modality for treating patients with colorectal liver metastases (review). HPB. 2004; 6(3): 133-139. 17. Bester L., Meteling B., Pocock N., Pavlakis N., Chua T.C., Saxena A., Morris D.L. Radioembolization versus standard care of hepatic metastases: Comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J. Vasc. Interv. Radiol. 2012; 23(1): 96-105. 18. Mahnken A.H., Spreafico C., Maleux G.,Helmberger T., Jacobs T.F. Standards of practice in transarterial radioembolization. Cardiovasc. Intervent. Radiol. 2013; 36(3): 613-622. 19. Brown R.E., Bower M.R., Metzger T.L., Scoggins C.R., McMaster K.M., Hall M.J., Tatum C., Martin R.C.G. Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: Is it safe? HPB. 2011; 13(2): 91-95. 20. Ibrahim S.M., Kulik L., Baker T., Ryu R.K., Mulcahy M.F., Abecassis M., Salem R., Lewandowski R.J. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc. Intervent. Radiol. 2012; 35(5): 1094-1101. 21. Tohme S., Sukato D., Chen H.-W., Amesur N., Zajko A.B., Humar A., Geller D.A., Marsh J.W., Tsung A. Yttrium- 90 radioembolization as a bridge to liver transplantation: A single-institution experience. J. Vasc. Interv. Radiol. 2013; 24(11): 1632-1638. 22. Hoffmann R.-T., Jakobs T.F., Kubisch C.H., Stemmler H.J., Trumm C., Tatsch K., Helmberger T.K., Reiser M.F. Radiofrequency ablation after selective internal radiation therapy with yttrium 90 microspheres in metastatic liver disease - is it feasible? Eur. J. Radiol. 2010; 74(1): 199-205. 23. Wasan H., Kennedy A., Coldwell D., Sangro B., Salem R. Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases (review). Am. J. Clin. Oncol. 2012; 35(3): 293-301. 24. Edeline J., Lenoir L., Boudjama K., Rolland Y, Boulic A., Le Du F., Pracht M., Raoul J.-L., Clement B., Garin E., Boucher E. Volumetric changes after 90Y radioembolization for hepatocellular carcinoma in cirrhosis: An option to portal vein embolization in a preoperative setting? Ann. Surg. Oncol. 2013; 20(8): 2518-2525. 25. Vouche M., Lewandowski R.J., Atassi R., Memon K., Gates V.L., Ryu R.K., Gaba R.C., Mulcahy M.F., Baker T., Sato K., Hickey R., Ganger D., Riaz A., Fryer J., Caicedo J.C., Abecassis M., Kulik L., Salem R. Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J. Hepatol. 2013; 59(5): 1029-1036. 26. Lam M.G.E.H., Louie J.D., Iagaru A.H., Goris M.L., Sze D.Y Safety of repeated yrrium-90 radioembolization. Cardiovasc. Intervent. Radiol. 2013; 36(5): 13201328. 27. Fiore F., Cappelli A., Rodrigues M., Ettorre G.M., Saltarelli A., Geatti O., Ahmadzadehfar H., Haug A.R., Izzo F., Giampalma E., Sangro B., Pizzi G., Notarianni E., Vit A., Wilhelm K., Jacobs T.F., Lastoria S. Comparison of the survival and tolerability of radioembolization in elderly vs younger patients with unresectable hepatocellular carcinoma. J. Hepatol. 2013; 59(4): 753-761.
